Kraig Biocraft Laboratories Inc
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
KBLBStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
EXHIBIT INDEX
| Exhibit No. | Description |
| 3.1 | Articles of Incorporation (1) |
| 3.2 | Articles of Amendment (2) |
| 3.3 | Articles of Amendment, filed with the Wyoming Secretary of State on November 15, 2013 (3) |
| 3.4 | Articles of Amendment, filed with the Wyoming Secretary of State on December 17, 2013 (4) |
| 3.5 | Bylaws(1) |
| 4.1 | Form of Warrant issued Mr. Jonathan R. Rice (5) |
| 4.2 | Form of Warrant issued pursuant to that certain Purchase Agreement dated as of March 8, 2019 (7) |
| 4.3 | Form of Convertible Debenture (8) |
| 4.4 | Form of Warrant(8) |
| 4.5 | Form of A&R Convertible Debenture(8) |
| 10.1 | Employment Agreement between Mr. Jonathan Rice and the Company (6) |
| 10.2 | Form of Purchase Agreement dated March 8, 2019 (7) |
| 10.3 | Form of Securities Purchase Agreement(8) |
| 10.4 | Form of Guaranty Agreement(8) |
| 10.5 | Form of Security Agreement(8) |
| 10.6 | Form of IP Security Agreement(8) |
| 10.7 | Form of Registration Rights Agreement(8) |
| 10.8 | Strategic Partnership Agreement (portions of the exhibit have been omitted because they (i) are not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed)(9) |
| 10.9 | Amendment (portions of the exhibit have been omitted because they (i) are not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed)(9) |
| 31.1 | Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith) |
| 31.2 | Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith) |
| 32.1 | Certification of the Principal Executive Officer pursuant to U.S.C. Section 1350 As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith) |
| 32.2 | Certification of the Principal Financial Officer pursuant to U.S.C. Section 1350 As adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith) |
| 101.INS | Inline XBRL Instance Document (filed herewith) |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 1. | Incorporated by reference to our Registration Statement on Form SB-2 (Reg. No. 333-146316) filed with the SEC on September 26, 2007. |
| 2. | Incorporated by reference to our Registration Statement on Form S-1 (Reg. No. 333-162316) filed with the SEC on October 2, 2009. |
| 3. | Incorporated by reference to our Current Report on Form 8-K filed with the SEC on November 22, 2013. |
| 4. | Incorporated by reference to our Current Report on Form 8-K filed with the SEC on December 19, 2013. |
| 6. | Incorporated by reference to our Current Report on Form 8-K filed with the SEC on January 21, 2015. |
| 7. | Incorporated by reference to our Current Report on Form 8-K filed with the SEC on March 11, 2019. |
| 8. | Incorporated by reference to our Current Report on Form 8-K filed with the SEC on March 26, 2021. |
| 9. | Incorporated by reference to our Current Report on Form 8-K filed with the SEC on January 26, 2021. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf of the undersigned thereunto duly authorized.
| Kraig Biocraft Laboratories, Inc. | ||
| (Registrant) | ||
| Date: August 14, 2024 | By: | /s/ Kim Thompson |
|---|---|---|
| Kim Thompson | ||
| President, Chief Executive Officer and | ||
| Chief Financial Officer (Principal Executive Officer and | ||
| Principal Financial and Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.